Cosmos Health Q3 2023: Revenue $12.8M (+7% YoY), net loss $3.35M, Adj. EBITDA -$1.1M

Cosmos Health Inc.

2023-Q3 EPS reported -$0.42 revenue$37,537,003

Revenue $12.8M (+7% YoY); gross margin declined to 9.5% from 14.9% due to logistics mix.
Net loss $3.35M vs $1.97M in Q3 2022; Adjusted EBITDA -$1.1M vs +$0.5M.
SG&A doubled to $4.0M on R&D, acquisition integration, stock-based comp, and provisions.
Total assets record $71.5M; stockholders' equity $44.2M ($3.4/share); debt reduced.
Reiterated 2026 guidance: >$180M revenue, >$20M EBITDA; plans to spin off R&D division.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cosmos Health Inc. reported the third quarter and nine months ended September 30, 2023 results: revenue $12.8 million. Guidance reaffirmed.

Period: the third quarter and nine months ended September 30, 2023
Revenue: $12.8 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

a business update and reported financial results for the third quarter and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights · Revenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded following the acquisition of the Bikas GP

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-23-008752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.